A review of augmentation therapy for alpha-1 antitrypsin deficiency

Expert Opinion on Biological Therapy

Volumn 12, Issue 6, 2012, Pages 685-700

  Mohanka, Manish ^a   Khemasuwan, Danai ^a   Stoller, James K ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin; Augmentation therapy; Cirrhosis; Emphysema; Gene therapy; Panniculitis; Protease inhibitor; Pulmonary function test

Indexed keywords

ALPHA 1 ANTITRYPSIN; GLASSIA; LEUKOCYTE ELASTASE; MOLECULAR THERAPY AGENT; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUGMENTATION THERAPY; AUTOPHAGY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; EMPHYSEMA; GENE THERAPY; HUMAN; POLYMERIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE ELASTASE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84861319134     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.676638     Document Type: Review

References (87)

1. Stoller JK, Aboussouan LS. Alpha-1 antitrypsin deficiency. Lancet 2005;365(9478):2225-2236
2. Silverman EK, Sandhaus RA. Clinical practice. Alpha-1 antitrypsin deficiency. N Engl J Med 2009;360(26):2749-2757
3. Hubbard RC, Crystal RG. Alpha-1 antitrypsin augmentation therapy for alpha-1 antitrypsin deficiency. Am J Med 1988;84(6A):52-62
4. Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of alpha-1 antitrypsin deficiency: A continuing problem. Chest 2005;128(4):1989-1994
5. Stoller JK, Aboussouan LS. Concise clinical review: Alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2012;185:246-259
6. Stoller JK, Gildea TR, Ries AL, National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007;83(1):241-251
7. Cassina PC, Teschler H, Konietzko N, et al. Two-year results after lung volume reduction surgery in alpha-1 antitrypsin deficiency versus smoker's emphysema. Eur Respir J 1998;12(5):1028-1032
8. Dauriat G, Mal H, Jebrak G, et al. Functional results of unilateral lung volume reduction surgery in alpha-1 antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis 2006;1(2):201-206
9. Talecris Biotherapeutics, Inc. U. Alpha-1 proteinase inhibitor (Human) Prolastin. Last updated 06/2008; [Last accessed 01/14/2012:6]
10. Talecris Biotherapeutics, Inc. U. Alpha-1 proteinase inhibitor (Human) Prolastin-C. Last updated 10/2009; [Last accessed 01/14/2012:2]
11. Alpha Therapeutic Corp. U. Alpha-1 proteinase inhibitor (Human) Aralast. Last updated 2002; [Last accessed 01/14/2012:8]
12. Baxter Healthcare Corp. U. Aralast NP [alpha-1 proteinase inhibitor (Human)]. [Last accessed 01/14/2012:13]
13. Aventis Behring LLC U. Alpha-1 proteinase inhibitor (Human) Zemaira. Last updated 07/2003; [Last accessed 01/14/2012:13]
14. Baxter Healthcare Corp. U. Glassia. Last updated 11/15/2011; [Last accessed 01/14/2012:2]
15. Instituto Grifols SA, Barcelona Spain. Trypsone/Trypsan package insert (Spanish). Last updated 10/2009; [Last accessed 01/14/2012:6]
16. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin 2011;27(3):579-588
17. Cowden DI, Fisher GE, Weeks RL. A pilot study comparing the purity, functionality and isoform composition of alpha-1 proteinase inhibitor (human) products. Curr Med Res Opin 2005;21(6):877-883
18. Kueppers F, Patel U. Differences in microheterogeneity and non-therapeutic protein content of three commercial preparations of purified human alpha-1 proteinase inhibitor. [abstract]. Chest Suppl 2005;128:262S
19. Fagerhol MK. Quantitative studies on the inherited variants of serum alpha-1 antitrypsin. Scand J Clin Lab Invest 1969;23(1):97-103
20. Vaughan L, Lorier MA, Carrell RW. Alpha-1 antitrypsin microheterogeneity. Isolation and physiological significance of isoforms. Biochim Biophys Acta 1982;701(3):339-345
21. Hodges LC, Laine R, Chan SK. Structure of the oligosaccharide chains in human alpha-1 protease inhibitor. J Biol Chem 1979;254(17):8208-8212
22. Mega T, Lujan E, Yoshida A. Studies on the oligosaccharide chains of human alpha-1 protease inhibitor. I. Isolation of glycopeptides. J Biol Chem 1980;255(9):4053-4056
23. Mega T, Lujan E, Yoshida A. Studies on the oligosaccharide chains of human alpha-1 protease inhibitor. II. Structure of oligosaccharides. J Biol Chem 1980;255(9):4057-4061
24. Kolarich D, Turecek PL, Weber A, et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha-1 proteinase inhibitor products used for replacement therapy. Transfusion 2006;46(11):1959-1977
25. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha-1 antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68(5):1158-1165
26. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha-1 antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316(17):1055-1062
27. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha-1 antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88(3):891-897
28. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: Effect of alpha-1 antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002;57(8):709-714
29. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1 antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160(6):1968-1975
30. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2002;165(11):1494-1498
31. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1 antitrypsin, Respitin. Chest 2002;122(1):66-74
32. Gottlieb DJ, Luisetti M, Stone PJ, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha-1 antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000;162(6):2069-2072
33. Stone PJ, Morris TA III, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1 antitrypsin-deficient humans. Respiration 1995;62(2):76-9
34. Seersholm N, Wencker M, Banik N, et al. Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1 antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) Alpha-1 AT Study Group. Eur Respir J 1997;10(10):2260-2263
35. The Alpha-1 Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin. Am J Respir Crit Care Med 1998;158(1):49-59
36. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha-1 antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-1472
37. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 2000;118(5):1480-1485
38. Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha-1 protease inhibitor deficiency before and during therapy with IV alpha-1 protease inhibitor. Chest 2001;119(3):737-744
39. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J 2009;33(6):1345-1353
40. Tonelli AR, Rouhani F, Li N, et al. Alpha-1 antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009;4:443-452
41. Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: An integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010;11:136
42. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha-1 antitrypsin deficiency: A meta-analysis. copd 2009;6(3):177-184
43. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010(7):CD007851
44. Chapman KR, Bradi AC, Paterson D, et al. Slower lung function decline during augmentation therapy in patients with alpha-1 antitrypsin deficiency (A1ATD): Results from the Canadian AIR registry. [abstract]. Proc Am Thorac Soc 2005;2:A808
45. American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168(7):818-900
46. Alpha-1 Antitrypsin Deficiency Task Force, Planning Committee/Executive Committee. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency: Executive summary. Respir Care 2003;48(11):1043-1047
47. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha-1 antitrypsin infusion in alpha-1 antitrypsin deficiency. Chest 1997;112(3):607-613
48. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1 antitrypsin deficiency. JAMA 1988;260(9):1259-1264
49. King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1 proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994;149(4 Pt 1):966-971
50. Meyer KC, Nunley DR, Dauber JH, et al. Neutrophils, unopposed neutrophil elastase, and alpha-1 antiprotease defenses following human lung transplantation. Am J Respir Crit Care Med 2001;164(1):97-102
51. Strange C, Stoller JK, Sandhaus RA, et al. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006;73(2):185-190
52. Tanash HA, Riise GC, Hansson L, et al. Survival benefit of lung transplantation in individuals with severe alpha-1 antitrypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant 2011;30(12):1342-1347
53. Sandhaus RA, Turino G, Stocks J, et al. Alpha-1 antitrypsin augmentation therapy for P.I.MZ heterozygotes: A cautionary note. Chest 2008;134(4):831-834
54. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha-1 antitrypsin: Patterns of use and adverse events. Chest 2003;123(5):1425-1434
55. Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha-1 antitrypsin deficiency-related pulmonary emphysema with human alpha-1 antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-Alpha-1 AT Study Group. Eur Respir J 1998;11(2):428-433
56. Bernhardt T, Cortes R. Post license safety of Prolastin [abstract]. Annual Congress of the European Respiratory Society; 2 - 6 September 2006; Munich Germany; # E2987
57. Stocks JM, Brantly M, Pollock D, et al. Multi-center study: The biochemical efficacy, safety and tolerability of a new alpha-1 proteinase inhibitor, Zemaira. copd 2006;3(1):17-23
58. Bergman G, Romberg V, Hubsch A. Safety and tolerability of an alpha-1 proteinase inhibitor: Results of four studies. [abstract]. Chest Meeting 2007;132:528B-9B
59. Stocks JM, Brantly ML, Wang-Smith L, et al. Pharmacokinetic comparability of prolastin-C to prolastin in alpha-1 antitrypsin deficiency: A randomized study. BMC Clin Pharmacol 2010;10:13
60. Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991;81(4):427-433
61. Alkins SA, O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha-1 antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000;117(3):875-880
62. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;167(10):1387-1392
63. Shermock KM, Gildea TR, Singer M, Stoller JK. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: A decision analysis. copd 2005;2(4):411-418
64. Lieberman J, Winter B, Sastre A. Alpha-1 antitrypsin Pi-types in 965 copd patients. Chest 1986;89(3):370-373
65. Blanco I, Lara B, de Serres F. Efficacy of alpha-1 antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis 2011;6:14
66. Shapiro L, Pott GB, Ralston AH. Alpha-1 antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 2001;15(1):115-122
67. Zhang B, Lu Y, Campbell-Thompson M, et al. Alpha-1 antitrypsin protects beta-cells from apoptosis. Diabetes 2007;56(5):1316-1323
68. Stoller JK. On the evidence that augmentation therapy helps asthma: Are storks really responsible for new babies? Monaldi Arch Chest Dis 2008;69(4):155-156
69. Brantly M, Campos M, Kueppers F, et al. Safety and pharmacokinetics of alpha-1 proteinase inhibitor in subjects with alpha-1 antitrypsin deficiency (SPARK). Available from: www.clinicaltrials.gov Identifier NCT01213043 August 31, 2011 [Last accessed 22 January 2012]
70. Hubbard RC, Casolaro MA, Mitchell M, et al. Fate of aerosolized recombinant DNA-produced alpha-1 antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989;86(2):680-684
71. Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha-1 antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha-1 antitrypsin deficiency. J Clin Invest 1989;84(4):1349-1354
72. Stolk J. International study evaluating the safety and efficacy of inhaled, human, alpha-1 antitrypsin (AAT) in alpha-1 antitrypsin deficient patients with emphysema. Available from: www.clinicaltrials.gov Identifier NCT01217671 June 13, 2011 [Last accessed January 22 2012]
73. Spencer LT, Humphries JE, Brantly ML. Transgenic Human Alpha-1 Antitrypsin Study Group. Antibody response to aerosolized transgenic human alpha-1 antitrypsin. N Engl J Med 2005;352(19):2030-2031
74. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1 antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Dev Ther 2011;5:391-405
75. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha-1 antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478(7369):391-394
76. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency: A preliminary study. J Pediatr Gastroenterol Nutr 2004;39(1):34-7
77. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha-1 antitrypsin-related cirrhosis. J Biol Chem 2002;277(9):6771-6774
78. Kaushal S, Annamali M, Blomenkamp K, et al. Rapamycin reduces intrahepatic alpha-1 antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 2010;235(6):700-709
79. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha-1 antitrypsin Z and reduces hepatic fibrosis. Science 2010;329(5988):229-232
80. Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet 2011;20(R1):R87-92
81. Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha-1 antitrypsin gene in alpha-1 antitrypsin-deficient subjects: Comparison with protein therapy. Hum Gene Ther 2000;11(7):1023-1032
82. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha-1 antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17(12):1177-1186
83. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009;106(38):16363-6368
84. Chulay JD, Ye GJ, Thomas DL, et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 2011;22(2):155-165
85. GOLD copd Committee. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www. goldcopd.org and http://www.goldcopd org/uploads/users/files/ GOLD-Pocket-2010Mar31.pdf 2011.[Last accessed 01/14/2012:90]
86. Strange C. The use of high resolution chest computed tomography in alpha-1 antitrypsin deficiency (QUANTUM-1). Available from: www.clinicaltrials. gov Identifier NCT00532805 July 30, 2009 [Last accessed 22 January 2012]
87. Stoller JK, Piliang M. Panniculitis in alpha-1 antitrypsin deficiency: A review. Clin Pulm Med 2008;15:113-117